報價延遲最少15分鐘:2024/05/14 21:28 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.82 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.66/-1.57
|
|
企業價值
522.70M
|
| 資產負債 |
|
每股賬面淨值
2.74
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
426.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/14 21:28 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines. |